18F-FDG Uptake Measurements in Malignant Solid Tumors on PET/CT and PET/MR

Completed · Phase 1

Conditions studied: Solid Tumor, Adult

In brief

In the current study, the investigators plan to expand the knowledge of Positron Emission Tomography/Magnetic Resonance (PET/MR) reliability by assessing the repeatability of fludeoxyglucose (FDG) standardized uptake values (SUV) measurements, as well as apparent diffusion coefficients (ADC) measurements, in a broad population of patients with malignant solid tumors.

Key facts

Study ID

NCT02717572

Run by

Washington University School of Medicine

People needed

19

Starts

2016-03-01

Expected to finish

2017-06-05

Last updated by the study team

2019-04-05

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients with histologically confirmed malignant solid tumors (local or metastatic, newly diagnosed or recurrent disease).
• Patient must have at least one lesion measuring ≥ 2.0 cm.
• 18 years of age or older.
• Ability to provide informed consent.

You may not qualify if…

• Cancer therapy within 30 days of baseline imaging.
• Uncontrolled intercurrent illness including, but not limited to active infections.
• Patients with insulin-dependent diabetes.
• Patients with metal devices in the body including, but not limited to metallic joint prostheses, artificial heart valves, pacemakers, and cochlear implants.
• Patients who are pregnant or nursing.
• Inability to tolerate 60 minutes of PET imaging.
• Inability to comply with study procedures.

Where it is running

• Washington University School of Medicine — St Louis, Missouri, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.